Designed for a rapid and accurate genotyping of HPV. Covering 22 types of HPV, including 18 high-risk types and 4 low-risk types, they can be used to detect the infection of HPV, identify women subject to high risk of cervical cancer, distinguish diseases caused by the infection of HPV from diseases with similar symptoms, help doctors make plan for personalized treatment, and evaluate the risk of postoperative recidivation.

CapitalBio Corporation was established on September 30, 2000. After 17 years of development, it now consists of five research institutes and five subsidiaries. The five research institutes are: Research Institute of Translational Medicine, Research Institute of Bioinformatics, Research Institute of Engineering, Research Institute of Health Science, and Research Institute of Health Technology. The five subsidiaries are: CapitalBio Technology Co., Ltd., CapitalBio Diagnostic Laboratory, CapitalBio eHealth Science & Technology (Beijing) Co., Ltd., CapitalBio Genomics Co., Ltd. and CapitalBio New View Diagnostic Technology Co., Ltd..

CapitalBio Corporation is a leading provider of life science solutions. It provides products and services in the fields of clinical diagnostics, scientific research, HLA typing, animal disease control, food safety testing, identification of traditional Chinese herbs, molecular breeding, NIPT, and liquid biopsy. It possesses more than 125,000m2 of R&D, production, operation, and service facilities.

CapitalBio Corporation possesses well-established quality management system. It is ISO 9001 and ISO 13485 certified. Its products are approved by China FDA and FDA in some other countries and are certified with appropriate CE, TUV/GS, and cTUVus certificates. Its lab is ISO17025 Certified and its HLA Typing Lab is ASHI certified.

Innovation drives CapitalBio Corporation's continuous growth in the Life Science technology field. By September 30, 2016, CapitalBio Corporation has made 272 applications for patens all over the world, most of which have been approved. The conversion rate of CapitalBio Corporation’s patents is as high as 56.8%. CapitalBio Corporation has built a strong reputation for R & D of biochip related instruments and its products have been awarded numerous prizes.

CapitalBio Corporation has established strategic partnerships with many life science companies in the world, as well as with distributors and dealers worldwide. It has offices in Hong Kong and the USA and its products have entered the clinical and research markets in more than 30 countries and regions.